Terns Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Terns Pharmaceuticals, Inc. (TERN) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-88.85-90.21-60.35-50.16-29.35
Depreciation & Amortization0.900.881.030.510.39
Deferred Income Tax0.020.140.390.220.69
Stock Based Compensation15.6325.5410.778.151.69
Change in Working Capital4.381.48-1.04-1.435.06
Change in Accounts Payable-0.371.15-0.721.73-1.15
Change in Other Working Capital4.750.33-0.32-3.156.21
Other Operating Activities0.020.140.390.22-7.64
Net Cash from Operating Activities-70.02-67.39-49.11-41.83-29.81
Investing Activities
Capital Expenditures-0.04-0.05-0.28-0.34-0.58
Purchases of Investments-12.37-275.78-139.73-119.367.28
Sales/Maturities of Investments157.57237.85117.7346.947.28
Net Cash from Investing Activities-12.41-37.99-22.27-119.706.69
Financing Activities
Debt Repayment0.000.000.00-12.880.00
Common Stock Issued164.3841.61167.25137.280.12
Other Financing Activities-0.39-0.34-0.4010.00-0.86
Net Cash from Financing Activities164.0041.95167.10134.3985.52
Summary
Effect of Forex Changes on Cash-0.060.12-0.18-0.030.08
Net Change in Cash81.51-63.4395.71-27.1662.48
Cash at Beginning of Period79.93143.2447.7074.8512.38
Cash at End of Period161.4479.93143.2447.7074.85
Free Cash Flow-70.06-67.44-49.38-42.17-30.39
Supplemental Disclosures
Income Taxes Paid0.060.030.000.240.18